Key facts
- It has raised $130.4M; the latest was Equity Crowdfunding ($3.5M) in Sep 2025.
- Notable investors include Earlybird Venture Capital, European Investment Bank, Aberdeen Investments (Scotland), EU Structural funds, Fountain Healthcare Partners — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Priothera
- ·The full record, as it builds
Funding rounds
No funding rounds for Priothera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Priothera
Developer of receptor modulators intended to improve the lives of patients suffering from haematological malignancies. The company's modulators reduce the egress of T cell subsets from lymphatic tissues, enabling patients receiving allogeneic stem cell transplants to get dual inhibition of graft versus host disease and enhance graft versus leukaemia benefits.
- Sector
- Healthcare
- HQ
- Dublin, Ireland
- Founded
- 2020
- Employees
- 25
- Website
- priothera.com/
- Ownership
- Privately Held (backing)
Priothera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Priothera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Priothera in its N-PORT filings yet. We sweep new filings monthly.